Founded in 1968, CRYOPAL develops, manufactures, and markets innovative products for home liquid oxygen therapy (respiratory failure treatment), as well as cryopreservation and transport of biological samples in the fields of health and medical research, pharmaceutical industry, genetics, and animal health.
Based in Bussy-Saint-Georges (Seine-et-Marne), the company has around 100 employees and generated sales revenue of €23 million in 2021, more than half of which comes from exports.
As part of its activities, AIR LIQUIDE has given a mandate to sell its subsidiary CRYOPAL to Trianon CF with the aim of conducting the search for counterparties in France and abroad and management buyout solutions. Finally, it was the offer of the Private Equity fund INITIATIVE & FINANCE associated with that of the management of CRYOPAL, led by its General Manager Olivier Lartigue, which was chosen to take over the company.
The intervention of Trianon CF focused on drafting the information memorandum, identifying, connecting and conducting discussions with potential buyers and investors, negotiating the interests of the sellers, managing the dataroom and Q&A sessions, as well as coordinating all the parties involved in the transaction.